Geoffrey R Oxnard

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
  2. pmc When progressive disease does not mean treatment failure: reconsidering the criteria for progression
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1234, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1534-41. 2012
  3. ncbi request reprint Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
    Arch Pathol Lab Med 136:1205-9. 2012
  4. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
  5. pmc Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
  6. pmc New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:5530-7. 2011
  7. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
  8. pmc Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung
    Andrew M Brunner
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women s Hospital, Boston, Massachusetts and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 8:1434-7. 2013
  9. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
  10. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012

Collaborators

Detail Information

Publications19

  1. pmc Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
    Geoffrey R Oxnard
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
    J Thorac Oncol 8:179-84. 2013
    ..Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies...
  2. pmc When progressive disease does not mean treatment failure: reconsidering the criteria for progression
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1234, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1534-41. 2012
    ....
  3. ncbi request reprint Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
    Arch Pathol Lab Med 136:1205-9. 2012
    ....
  4. pmc Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 17:6322-8. 2011
    ..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI...
  5. pmc Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:6298-303. 2011
    ..To examine this observation and define the course of patients following TKI discontinuation, we systematically evaluated patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib...
  6. pmc New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:5530-7. 2011
    ..In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies...
  7. pmc Screening for germline EGFR T790M mutations through lung cancer genotyping
    Geoffrey R Oxnard
    Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1049-52. 2012
    ..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations...
  8. pmc Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung
    Andrew M Brunner
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women s Hospital, Boston, Massachusetts and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 8:1434-7. 2013
    ..An open-label phase II trial with dasatinib was carried out to determine the response rates in patients with SqCC who had previously failed standard chemotherapy and to correlate responses with patient genotype...
  9. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Geoffrey R Oxnard
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
    Clin Cancer Res 17:1616-22. 2011
    ..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI...
  10. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  11. pmc Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Lung Cancer 78:161-6. 2012
    ..Compare the clinical characteristics, rate of recurrent venous thromboembolism (VTE) and outcome of suspected and unsuspected pulmonary embolism (PE) detected on computed tomography in patients with lung cancer...
  12. ncbi request reprint Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer
    Ravi B Parikh
    Harvard Medical School, Boston, Massachusetts
    Int J Radiat Oncol Biol Phys 89:880-7. 2014
    ....
  13. pmc New targetable oncogenes in non-small-cell lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 31:1097-104. 2013
    ....
  14. doi request reprint Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes
    Geoffrey R Oxnard
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Clin Cancer Res 19:1634-6. 2013
    ..In the accompanying article, the authors carried out a meta-analysis of the published literature on EGF receptor (EGFR) genotype and erlotinib/gefitinib sensitivity to develop a publicly accessible database to inform patient care...
  15. pmc Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Oncologist 18:1214-20. 2013
    ..We observed an improved response rate but no difference in progression-free survival or overall survival. A larger prospective clinical trial is needed to evaluate this promising strategy further. ..
  16. ncbi request reprint Non-small cell lung cancer in octogenarians: treatment practices and preferences
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Thorac Oncol 2:1029-35. 2007
    ..Treatment practices in this patient population are poorly described. In this report, we describe the treatment of a population of very elderly patients with NSCLC at a large teaching hospital...
  17. pmc Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
    Geoffrey R Oxnard
    Authors Affiliations Department of Medical Oncology Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 20:1698-705. 2014
    ..We sought to determine whether droplet digital PCR (ddPCR) of cfDNA would allow highly specific and quantitative assessment of tumor genotype...
  18. ncbi request reprint Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
    Geoffrey R Oxnard
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:392-9. 2010
    ..Currently active trials are referenced using their ClinicalTrials.gov identifier...
  19. ncbi request reprint Modeling of mesothelioma growth demonstrates weaknesses of current response criteria
    Geoffrey R Oxnard
    Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, USA
    Lung Cancer 52:141-8. 2006
    ..Application of the RECIST response criteria to mesothelioma thickness measurements yields PR and PD classifications based on smaller volume changes than for spherical tumors...